Fate Therapeutics (NASDAQ:FATE)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Wednesday. They presently have a $7.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective would suggest a potential upside of 50.54% from the stock’s previous close.

Several other brokerages have also issued reports on FATE. BMO Capital Markets reiterated a “buy” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research note on Thursday, November 2nd. ValuEngine lowered shares of Fate Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, December 1st. Leerink Swann reiterated an “outperform” rating and issued a $7.00 price target on shares of Fate Therapeutics in a research note on Friday, September 8th. Raymond James Financial reiterated a “buy” rating on shares of Fate Therapeutics in a research note on Tuesday. Finally, Zacks Investment Research upgraded shares of Fate Therapeutics from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a research note on Friday, September 8th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $6.79.

Shares of Fate Therapeutics (NASDAQ:FATE) traded up $0.22 during trading hours on Wednesday, hitting $4.65. 2,657,994 shares of the company were exchanged, compared to its average volume of 297,248. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.32. Fate Therapeutics has a fifty-two week low of $2.40 and a fifty-two week high of $5.68.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.01). Fate Therapeutics had a negative net margin of 935.09% and a negative return on equity of 64.55%. The business had revenue of $1.03 million during the quarter, compared to analyst estimates of $0.95 million. The company’s quarterly revenue was up .0% on a year-over-year basis. research analysts predict that Fate Therapeutics will post -0.99 earnings per share for the current fiscal year.

In other news, General Counsel Cindy Tahl sold 8,091 shares of the business’s stock in a transaction dated Monday, October 16th. The shares were sold at an average price of $3.85, for a total transaction of $31,150.35. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Daniel D. Shoemaker sold 13,225 shares of the business’s stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $3.87, for a total transaction of $51,180.75. The disclosure for this sale can be found here. 10.88% of the stock is owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the company. Hochman Cole Investment Advisors Inc. acquired a new position in shares of Fate Therapeutics during the 3rd quarter worth about $158,000. New York State Common Retirement Fund acquired a new position in shares of Fate Therapeutics during the 2nd quarter worth about $131,000. Rhumbline Advisers acquired a new position in shares of Fate Therapeutics during the 2nd quarter worth about $133,000. Morgan Stanley increased its stake in shares of Fate Therapeutics by 9.8% during the 1st quarter. Morgan Stanley now owns 611,646 shares of the biopharmaceutical company’s stock worth $2,783,000 after purchasing an additional 54,615 shares during the last quarter. Finally, Russell Investments Group Ltd. acquired a new position in shares of Fate Therapeutics during the 3rd quarter worth about $234,000. Institutional investors own 60.97% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/12/13/fate-therapeutics-fate-buy-rating-reiterated-at-hc-wainwright.html.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Analyst Recommendations for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.